LATEST ONCOPRESCRIBE UPDATES
ASCO Recommendations for Sentinel Lymph Node Biopsy (SLNB) and Axillary Management in Early-Stage Breast Cancer
Beyond TNM Staging: How ctDNA Is Reshaping Risk Stratification in Stage III Colon Cancer
FDA Approves ENHERTU® for Neoadjuvant Therapy in High-Risk HER2-Positive Early Breast Cancer
FDA Approves ENHERTU® in Postneoadjuvant Care for High-Risk HER2-Positive Early Breast Cancer
Expanding systemic treatment options in neuroendocrine tumors
FDA Approves Next Generation Vepdegestrant for ER-positive, HER2-negative, ESR1-Mutated Advanced Breast Cancer
Advanced Gastroesophageal Cancer: ASCO Guideline Update
Emerging Real-World Evidence Positions GLP-1 Receptor Agonists in Colorectal Cancer Prevention
NEW REGIMENS ADDED
VYLOY® with mFOLFOX 6 - for Gastric and GEJ cancer
VYLOY® (Zolbetuximab) with ELOXATIN® (Oxaliplatin), 5-FU and Leucovorin. Regimen for Gastric and GastroEsophageal Junction adenocarcinoma whose tumors are Claudin (CLDN) 18.2 positiveVYLOY® with CAPOX - for Gastric and GEJ cancer
VYLOY® (Zolbetuximab) with ELOXATIN® (Oxaliplatin) and XELODA® (Capecitabine). Regimen for Gastric and GastroEsophageal Junction adenocarcinoma whose tumors are Claudin (CLDN) 18.2 positiveENHERTU® - for Breast Cancer
Single Agent ENHERTU® (fam-trastuzumab deruxtecan-nxki) for Ultralow Metastatic Breast CancerOPDIVO® and YERVOY® with Limited Course Chemotherapy - for Non Small Cell Lung Cancer
OPDIVO® (Nivolumab) and YERVOY® (Ipilimumab) with 2 cycles of TAXOL® (Paclitaxel) and PARAPLATIN®(Carboplatin) - for advanced NSCLCJAYPIRCA® - for Mantle Cell Lymphoma
JAYPIRCA® (Pirtobrutinib) for Mantle Cell Lymphoma
Curbside Consultation
Bottom Ad
Advertisement
Subscribe
